EP3436593A4 - Verfahren zur hitze-inaktivierung des adenovirus - Google Patents

Verfahren zur hitze-inaktivierung des adenovirus Download PDF

Info

Publication number
EP3436593A4
EP3436593A4 EP17776462.8A EP17776462A EP3436593A4 EP 3436593 A4 EP3436593 A4 EP 3436593A4 EP 17776462 A EP17776462 A EP 17776462A EP 3436593 A4 EP3436593 A4 EP 3436593A4
Authority
EP
European Patent Office
Prior art keywords
adenovirus
methods
heat inactivation
inactivation
heat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP17776462.8A
Other languages
English (en)
French (fr)
Other versions
EP3436593A1 (de
EP3436593B1 (de
Inventor
Christopher J. MORRISON
James D. MARATT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ultragenyx Pharmaceutical Inc
Original Assignee
Dimension Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dimension Therapeutics Inc filed Critical Dimension Therapeutics Inc
Priority to EP22199443.7A priority Critical patent/EP4159867A1/de
Publication of EP3436593A1 publication Critical patent/EP3436593A1/de
Publication of EP3436593A4 publication Critical patent/EP3436593A4/de
Application granted granted Critical
Publication of EP3436593B1 publication Critical patent/EP3436593B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP17776462.8A 2016-03-28 2017-03-28 Verfahren zur hitze-inaktivierung des adenovirus Active EP3436593B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP22199443.7A EP4159867A1 (de) 2016-03-28 2017-03-28 Verfahren zur hitze-inaktivierung des adenovirus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662314116P 2016-03-28 2016-03-28
PCT/US2017/024545 WO2017172772A1 (en) 2016-03-28 2017-03-28 Methods of heat inactivation of adenovirus

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP22199443.7A Division EP4159867A1 (de) 2016-03-28 2017-03-28 Verfahren zur hitze-inaktivierung des adenovirus
EP22199443.7A Division-Into EP4159867A1 (de) 2016-03-28 2017-03-28 Verfahren zur hitze-inaktivierung des adenovirus

Publications (3)

Publication Number Publication Date
EP3436593A1 EP3436593A1 (de) 2019-02-06
EP3436593A4 true EP3436593A4 (de) 2019-10-16
EP3436593B1 EP3436593B1 (de) 2022-11-23

Family

ID=59966403

Family Applications (2)

Application Number Title Priority Date Filing Date
EP22199443.7A Pending EP4159867A1 (de) 2016-03-28 2017-03-28 Verfahren zur hitze-inaktivierung des adenovirus
EP17776462.8A Active EP3436593B1 (de) 2016-03-28 2017-03-28 Verfahren zur hitze-inaktivierung des adenovirus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP22199443.7A Pending EP4159867A1 (de) 2016-03-28 2017-03-28 Verfahren zur hitze-inaktivierung des adenovirus

Country Status (18)

Country Link
US (3) US11013774B2 (de)
EP (2) EP4159867A1 (de)
JP (3) JP7356224B2 (de)
KR (1) KR102389674B1 (de)
CN (1) CN109196106A (de)
AU (1) AU2017241777B2 (de)
BR (1) BR112018069703A2 (de)
CA (1) CA3018380A1 (de)
DK (1) DK3436593T3 (de)
ES (1) ES2938833T3 (de)
FI (1) FI3436593T3 (de)
HU (1) HUE061100T2 (de)
IL (1) IL261914B2 (de)
LT (1) LT3436593T (de)
PL (1) PL3436593T3 (de)
PT (1) PT3436593T (de)
SG (1) SG11201808183PA (de)
WO (1) WO2017172772A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017009497A2 (pt) 2014-11-05 2018-02-06 Voyager Therapeutics, Inc. polinucleotídeos de aadc para o tratamento da doença de parkinson
ES2878451T3 (es) 2014-11-14 2021-11-18 Voyager Therapeutics Inc Polinucleótidos moduladores
US10597660B2 (en) 2014-11-14 2020-03-24 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
EP3230441A4 (de) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur herstellung von scaav
KR20240056729A (ko) 2016-05-18 2024-04-30 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
US20210238580A1 (en) * 2018-05-11 2021-08-05 Qiagen Gmbh Lysis method for plant samples
US20220017922A1 (en) 2018-12-18 2022-01-20 Ultragenyx Pharmaceutical Inc. Methods and compositions for treating glycogen storage diseases
CA3136246A1 (en) 2019-04-12 2020-10-15 Ultragenyx Pharmaceutical Inc. Engineered producer cell lines and methods of making and using the same
WO2023172491A1 (en) 2022-03-07 2023-09-14 Ultragenyx Pharmaceutical Inc. Modified batch aav production systems and methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688676A (en) * 1995-06-07 1997-11-18 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
WO2005118792A1 (en) * 2004-06-01 2005-12-15 Avigen, Inc. Compositions and methods to prevent aav vector aggregation

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5387484A (en) 1992-07-07 1995-02-07 International Business Machines Corporation Two-sided mask for patterning of materials with electromagnetic radiation
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
JP4216350B2 (ja) * 1994-09-19 2009-01-28 大日本住友製薬株式会社 動物細胞感染用の組換えｄｎａウイルスベクター
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
WO1996017947A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
US6924128B2 (en) 1994-12-06 2005-08-02 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6027931A (en) 1995-08-03 2000-02-22 Avigen, Inc. High-efficiency AA V helper functions
ES2099678B1 (es) * 1995-11-03 1998-02-16 Grifols Grupo Sa Procedimiento para la inactivacion de virus en proteinas.
US6004797A (en) * 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
JP2001506133A (ja) 1996-12-18 2001-05-15 ターゲティッド ジェネティクス コーポレイション 組換えａａｖベクターの産生における使用のための、ａａｖスプリット−パッケージング遺伝子およびこのような遺伝子を含む細胞株
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
AU9319198A (en) 1997-09-19 1999-04-05 Trustees Of The University Of Pennsylvania, The Methods and vector constructs useful for production of recombinant aav
IT1297074B1 (it) 1997-11-21 1999-08-03 Angeletti P Ist Richerche Bio Forme ormone-dipendenti delle proteine rep del virus adeno-associato (aav-2), sequenze di dna codificanti per esse, vettori che le
WO2000009675A1 (en) * 1998-08-14 2000-02-24 Aventis Pharmaceuticals Products Inc. Adenovirus formulations for gene therapy
EP1124976A1 (de) 1998-10-27 2001-08-22 Crucell Holland B.V. Verbesserte produktion von aav-vektoren
DE19905501B4 (de) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
MXPA01010124A (es) * 1999-04-09 2002-06-26 Aventis Pharma Sa Composiciones destinada a la conservacion de adenovirus recombinantes infecciosos.
US20040235173A1 (en) 2000-07-03 2004-11-25 Gala Design, Inc. Production of host cells containing multiple integrating vectors by serial transduction
DE10061533B4 (de) 2000-12-11 2006-05-04 Amphenol-Tuchel Electronics Gmbh Selbsttragende Kontaktfeder, insbesondere für einen Smartcard-Connector
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
US7271002B2 (en) 2001-11-09 2007-09-18 United States Of America, Represented By The Secretary, Department Of Health And Human Services Production of adeno-associated virus in insect cells
CA2369985A1 (en) 2002-01-18 2003-07-18 Duke University Generation of recombinant adeno-associated viral vectors by a complete adenovirus-mediated approach
US7510872B2 (en) 2003-02-26 2009-03-31 Nationwide Children's Hospital Recombinant adeno-associated virus production
US7195394B2 (en) 2004-07-19 2007-03-27 Vijay Singh Method for resonant wave mixing in closed containers
US8980247B2 (en) 2004-10-21 2015-03-17 The Penn State Research Foundation Parvovirus methods and compositions for killing neoplastic cells
US8163543B2 (en) 2005-10-20 2012-04-24 Amsterdam Molecular Therapeutics B.V. AAV vectors produced in insect cells
AU2007245192B2 (en) * 2006-03-31 2012-04-12 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
AU2007261806B2 (en) 2006-06-21 2013-08-15 Uniqure Ip B.V. Vectors with modified initiation codon for the translation of AAV-Rep78 useful for production of AAV in insect cells
GB0706638D0 (en) 2007-04-04 2007-05-16 Mbda Uk Ltd A high-dielectric material
US8580755B2 (en) 2008-02-19 2013-11-12 University Of Rochester Methods and compositions for treating inflammatory conditions
CA2742151A1 (en) 2008-11-07 2010-05-14 Intelligentnano Inc. Transfection with magnetic nanoparticles and ultrasound
PL3067417T3 (pl) * 2009-06-16 2019-02-28 Genzyme Corporation Udoskonalone sposoby oczyszczania rekombinowanych wektorów AAV
WO2013096955A1 (en) 2011-12-23 2013-06-27 Case Western Reserve University Targeted gene modification using hybrid recombinant adeno-associated virus
AU2014205604B2 (en) 2013-01-08 2020-01-02 Genzyme Corporation Use of iNOS inhibitors to increase viral yield in culture

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688676A (en) * 1995-06-07 1997-11-18 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
WO2005118792A1 (en) * 2004-06-01 2005-12-15 Avigen, Inc. Compositions and methods to prevent aav vector aggregation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
E. D. HOROWITZ ET AL: "Biophysical and Ultrastructural Characterization of Adeno-Associated Virus Capsid Uncoating and Genome Release", JOURNAL OF VIROLOGY., vol. 87, no. 6, 26 December 2012 (2012-12-26), US, pages 2994 - 3002, XP055615729, ISSN: 0022-538X, DOI: 10.1128/JVI.03017-12 *
LIU ET AL: "Effect of magnesium ions on the thermal stability of human poly(A)-specific ribonuclease", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 581, no. 5, 24 February 2007 (2007-02-24), pages 1047 - 1052, XP005916868, ISSN: 0014-5793, DOI: 10.1016/J.FEBSLET.2007.02.008 *
V. RAYAPROLU ET AL: "Comparative Analysis of Adeno-Associated Virus Capsid Stability and Dynamics", JOURNAL OF VIROLOGY., vol. 87, no. 24, 25 September 2013 (2013-09-25), US, pages 13150 - 13160, XP055511936, ISSN: 0022-538X, DOI: 10.1128/JVI.01415-13 *
WRIGHT J F ET AL: "Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation", MOLECULAR THERAPY,, vol. 12, no. 1, 1 July 2005 (2005-07-01), pages 171 - 178, XP004974961, ISSN: 1525-0016, DOI: 10.1016/J.YMTHE.2005.02.021 *

Also Published As

Publication number Publication date
DK3436593T3 (da) 2023-02-20
KR102389674B1 (ko) 2022-04-21
WO2017172772A1 (en) 2017-10-05
FI3436593T3 (fi) 2023-03-16
US11013774B2 (en) 2021-05-25
IL261914A (en) 2018-10-31
PL3436593T3 (pl) 2023-03-27
AU2017241777B2 (en) 2022-02-03
HUE061100T2 (hu) 2023-05-28
EP4159867A1 (de) 2023-04-05
JP2022166304A (ja) 2022-11-01
US20240252562A1 (en) 2024-08-01
ES2938833T3 (es) 2023-04-17
KR20180130531A (ko) 2018-12-07
JP2019509747A (ja) 2019-04-11
PT3436593T (pt) 2023-01-31
JP2021072838A (ja) 2021-05-13
LT3436593T (lt) 2023-03-10
CA3018380A1 (en) 2017-10-05
US20220072073A1 (en) 2022-03-10
CN109196106A (zh) 2019-01-11
EP3436593A1 (de) 2019-02-06
BR112018069703A2 (pt) 2019-02-05
US11944658B2 (en) 2024-04-02
JP7356224B2 (ja) 2023-10-04
SG11201808183PA (en) 2018-10-30
EP3436593B1 (de) 2022-11-23
US20190083554A1 (en) 2019-03-21
IL261914B1 (en) 2023-03-01
AU2017241777A1 (en) 2018-10-11
IL261914B2 (en) 2023-07-01

Similar Documents

Publication Publication Date Title
EP3436593A4 (de) Verfahren zur hitze-inaktivierung des adenovirus
EP3218942A4 (de) Heiz- und kühltechnologien
EP3185937A4 (de) Thermische modulation eines inhalierbaren medikaments
EP3160405A4 (de) Behandlung des ohres
EP3180671A4 (de) Ausgeglichene steuerung der prozessortemperatur
EP3119401A4 (de) Cenicriviroc zur behandlung von fibrose
EP3134436A4 (de) Behandlung von h-ras-gesteuerten tumoren
EP3125776A4 (de) Gewebeisolator
EP3104083A4 (de) Erwärmungskocher
EP3099746A4 (de) Silikongelzusammensetzung
EP3194157A4 (de) Vakuumunterstützter wärmeverteiler
EP3174525A4 (de) Formulierungen für das ohr zur behandlung von cerumen obturans
EP3287706A4 (de) Wärmequelleneinheit
EP3193905A4 (de) Verfahren zur behandlung von gebärmutterhalskrebs
EP3447393A4 (de) Wärmequelleneinheit
EP3122349A4 (de) Zusammensetzungen zur behandlung von autodigestion
EP3185910A4 (de) Verfahren und zusammensetzungen zur krebsbehandlung
EP3441684A4 (de) Wärmequelleneinheit
EP3362205A4 (de) Verfahren zur verbesserung der wärmebehandlung von gussteilen
EP3249329A4 (de) Wärmebehandlungsvorrichtung
EP3367010A4 (de) Wärmequellensystem
EP3180011A4 (de) Immuntherapie zur behandlung von krebs
EP3315875A4 (de) Wärmequellenvorrichtung
EP3447396A4 (de) Wärmequelleneinheit
EP3341006A4 (de) Zusammensetzungen und verfahren zur behandlung von nervenschäden

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180914

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: MARATT, JAMES, D.

Inventor name: MORRISON, CHRISTOPHER, J.

A4 Supplementary search report drawn up and despatched

Effective date: 20190913

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 7/04 20060101ALI20190910BHEP

Ipc: C12N 15/864 20060101ALI20190910BHEP

Ipc: C12N 15/861 20060101AFI20190910BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ULTRAGENYX PHARMACEUTICAL INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20201223

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20220208

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20220715

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602017063950

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1533163

Country of ref document: AT

Kind code of ref document: T

Effective date: 20221215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3436593

Country of ref document: PT

Date of ref document: 20230131

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20230125

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20230213

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20221123

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2938833

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20230417

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20230400275

Country of ref document: GR

Effective date: 20230410

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E061100

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221123

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221123

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230323

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221123

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230419

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221123

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221123

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602017063950

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221123

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221123

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221123

26N No opposition filed

Effective date: 20230824

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221123

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LT

Payment date: 20230731

Year of fee payment: 8

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1533163

Country of ref document: AT

Kind code of ref document: T

Effective date: 20221123

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20240227

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20240321

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LT

Payment date: 20240305

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240320

Year of fee payment: 8

Ref country code: IE

Payment date: 20240312

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20240319

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20240220

Year of fee payment: 8

Ref country code: HU

Payment date: 20240220

Year of fee payment: 8

Ref country code: FI

Payment date: 20240320

Year of fee payment: 8

Ref country code: DE

Payment date: 20240325

Year of fee payment: 8

Ref country code: CZ

Payment date: 20240221

Year of fee payment: 8

Ref country code: GB

Payment date: 20240325

Year of fee payment: 8

Ref country code: PT

Payment date: 20240325

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20240318

Year of fee payment: 8

Ref country code: SE

Payment date: 20240319

Year of fee payment: 8

Ref country code: PL

Payment date: 20240202

Year of fee payment: 8

Ref country code: NO

Payment date: 20240228

Year of fee payment: 8

Ref country code: IT

Payment date: 20240320

Year of fee payment: 8

Ref country code: FR

Payment date: 20240327

Year of fee payment: 8

Ref country code: DK

Payment date: 20240125

Year of fee payment: 8

Ref country code: BE

Payment date: 20240325

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240401

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240412

Year of fee payment: 8